sb 202190 has been researched along with Insulin Resistance in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Insulin Resistance: Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Lahham, R | 1 |
| Deford, JH | 1 |
| Papaconstantinou, J | 1 |
1 other study available for sb 202190 and Insulin Resistance
| Article | Year |
|---|---|
Mitochondrial-generated ROS down regulates insulin signaling via activation of the p38MAPK stress response pathway.
Topics: Animals; Cells, Cultured; Hepatocytes; Imidazoles; Insulin Receptor Substrate Proteins; Insulin Resi | 2016 |